Actualités Science 37 Holdings Inc - SNCE | Actions NASDAQ

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial

MORRISVILLE, N.C., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research

MORRISVILLE, N.C., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Science 37, the leader in expanding patient access to...

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial

MORRISVILLE, N.C., April 08, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

MORRISVILLE, N.C., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

MORRISVILLE, N.C., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Today, Science 37, a leader in enhancing patient access...

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to...

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

RESEARCH TRIANGLE PARK, N.C., June 27, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient...

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- In a release issued under the same headline...

Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

RESEARCH TRIANGLE PARK, N.C., June 12, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc., a leader in...

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

RESEARCH TRIANGLE PARK, N.C., May 13, 2024 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. today announced the...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Science 37 Holdings Inc (SNCE)

Votre Hub pour des idées et discussions en direct en temps réel

Science 37 Holdings Inc (SNCE) Actualités

Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial

Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Science 37 Holdings Inc (SNCE)

Votre Hub pour des idées et discussions en direct en temps réel

Science 37 Holdings Inc (SNCE) Actualités

Science 37 Completes Third FDA Inspection, Validating Quality of its Direct-to-Patient Site in Pivotal Phase 3 Rare Disease Trial

Science 37 and Catalent Announce Partnership Enabling Universal Access to Clinical Research

Science 37 Completes Second FDA Inspection as Enrollment Leader in Phase 3 Asthma Trial

Science 37 Appoints Tyler Van Horn as CEO to Lead Next Era of Patient-Access Innovation

Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 Rare Disease Trial

Science 37 Earns Frost & Sullivan’s 2024 Global Company of the Year Award for Decentralized Clinical Trials

Science 37 Unveils New Corporate Headquarters in Research Triangle Park, NC

Science 37 Enrolls 42% of Trial Cohort in 8 Weeks

Science 37 Quickly Impacts Performance in Under-Enrolling Clinical Trials

CORRECTION-- Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Surpasses Enrollment Goals, Accelerates Phase 2 Rare Disease Clinical Trial

Science 37 Metasite™ Undergoes Successful FDA Inspection, Marking Major Milestone in Virtual Site Quality Assurance and Compliance

Science 37 Wins 2024 MedTech Breakthrough Award for “Clinical Efficiency Innovation”

Science 37 Delivers 22x Faster Enrollment than Traditional Methods in Phase 3 Asthma Clinical Trial

Science 37 Provides Fully Consented Patients to Sites to Supplement Enrollment

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Sign up for FREE and get:

Supprimer les publicités